QQ客服 官方微博 反馈留言

	Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
	Xie, Jie; Cao, Jun; Wang, Jing-fen; Zhang, Bai-hong; Zeng, Xiao-hua; Zheng, Hong; Zhang, Yang; Cai, Li; Wu, Yu-dong; Yao, Qiang
刊名	BREAST CANCER RESEARCH AND TREATMENT
	2018
卷号	168期号:2
关键词	Breast cancer Multicenter study PEG-rhG-CSF Neutropenia
ISSN号	0167-6806
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3415054
专题	昆明医科大学
推荐引用方式 GB/T 7714	Xie, Jie,Cao, Jun,Wang, Jing-fen,et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study[J]. BREAST CANCER RESEARCH AND TREATMENT,2018,168(2).
APA	Xie, Jie.,Cao, Jun.,Wang, Jing-fen.,Zhang, Bai-hong.,Zeng, Xiao-hua.,...&Hu, Xi-chun.(2018).Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.BREAST CANCER RESEARCH AND TREATMENT,168(2).
MLA	Xie, Jie,et al."Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study".BREAST CANCER RESEARCH AND TREATMENT 168.2(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。